<DOC>
	<DOCNO>NCT00609791</DOCNO>
	<brief_summary>RATIONALE : Gathering information patient different age receive paclitaxel albumin-stabilized nanoparticle formulation metastatic breast cancer may help doctor understand age patient change way drug work . PURPOSE : This phase II trial study well paclitaxel albumin-stabilized nanoparticle formulation work treat patient different age metastatic breast cancer .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Patients Different Ages With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine age-related change pharmacokinetics ( pK ) weekly paclitaxel albumin-stabilized nanoparticle formulation ( nab-paclitaxel ) patient metastatic breast cancer . - To determine age-related change pharmacodynamics ( toxicity ) nab-paclitaxel patient . Secondary - To determine response time progression patient . - To explore predictor pK parameter patient . - To explore predictor need dose reduction , dose delay , grade 3 4 toxicity patient . OUTLINE : Patients stratify age year ( &lt; 50 vs 50-60 v 60-70 v &gt; 70 ) . Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute daily day 1 , 8 , 15 plan . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Blood drawn pharmacokinetic study periodically course 1 . Patients complete questionnaire regard risk factor would predict pharmacokinetic parameter baseline , prior third course treatment , end study . Data collect include medical characteristic , demographic , functional status , comorbidity , psychological status , social function support , nutritional status , cognition .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis metastatic breast cancer Any estrogen receptor , progesterone receptor , HER2/neu status allow long patient receive paclitaxel albuminstabilized nanoparticle formulation alone First secondline chemotherapy treatment metastatic disease plan Exclusion criterion : Untreated CNS metastases symptomatic CNS metastasis require escalate dos corticosteroid PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN ( unless bone metastasis present absence liver metastasis ) Bilirubin ≤ 1.5 mg/dL Peripheral neuropathy ≤ grade 1 Creatinine clearance ≥ 30 mL/min ( calculated 24hour ) Negative pregnancy test Fertile patient must use effective contraception Not pregnant nursing No known history allergic reaction paclitaxel No serious uncontrolled infection Ability understand willingness sign write informed consent document PRIOR CONCURRENT THERAPY : See Disease Characteristics No ≥ grade 2 toxicity prior therapy ( alopecia ) No taxane adjuvant therapy metastatic disease within past 12 month No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>